Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Cortes

Showing results (441-450 of 584) with videos related to

Pageof 59
Sort By:
Blood Advances|March 16, 2021
Older adults with newly diagnosed high-risk/secondary AML who achieved remission with CPX-351: phase 3 post hoc analysesTara L Lin, David A Rizzieri, Daniel H Ryan, et al.
Leukemia|July 10, 2012
MK-0457, an Aurora kinase and BCR-ABL inhibitor, is active in patients with BCR-ABL T315I leukemiaF J Giles, R T Swords, A Nagler, et al.
Blood|August 26, 2011
Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinibJorge E Cortes, Hagop M Kantarjian, Tim H Brümmendorf, et al.
The Lancet. Haematology|December 22, 2015
Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm, phase 1/2 studyCourtney D DiNardo, Naval Daver, Elias Jabbour, et al.
Annals of Hematology|May 12, 2021
Correction to: Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trialMichael Heuser, B Douglas Smith, Walter Fiedler, et al.
Journal of Orthopaedic Research : Official Publication of the Orthopaedic Research Society|January 28, 2014
Prevention of late PJIAntonia Chen, Fares Haddad, Paul Lachiewicz, et al.
American Journal of Hematology|January 23, 2016
Prognostic impact of persistent cytogenetic abnormalities at complete remission in adult patients with acute lymphoblastic leukemiaNicholas J Short, Hagop M Kantarjian, Elias J Jabbour, et al.
Frontiers in Oncology|October 16, 2018
Initial Report of a Phase I Study of LY2510924, Idarubicin, and Cytarabine in Relapsed/Refractory Acute Myeloid LeukemiaPrajwal Boddu, Gautam Borthakur, Mythili Koneru, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 13, 2019
Phase II Trial of MEK Inhibitor Binimetinib (MEK162) in RAS-mutant Acute Myeloid LeukemiaAbhishek Maiti, Kiran Naqvi, Tapan M Kadia, et al.
American Journal of Hematology|March 15, 2016
Long-term evaluation of cardiac and vascular toxicity in patients with Philadelphia chromosome-positive leukemias treated with bosutinibJorge E Cortes, H Jean Khoury, Hagop Kantarjian, et al.
Pageof 59

Showing results (441-450 of 584) with videos related to

Sort By:
Pageof 59
Blood Advances|March 16, 2021
Older adults with newly diagnosed high-risk/secondary AML who achieved remission with CPX-351: phase 3 post hoc analysesTara L Lin, David A Rizzieri, Daniel H Ryan, et al.
Leukemia|July 10, 2012
MK-0457, an Aurora kinase and BCR-ABL inhibitor, is active in patients with BCR-ABL T315I leukemiaF J Giles, R T Swords, A Nagler, et al.
Blood|August 26, 2011
Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinibJorge E Cortes, Hagop M Kantarjian, Tim H Brümmendorf, et al.
The Lancet. Haematology|December 22, 2015
Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm, phase 1/2 studyCourtney D DiNardo, Naval Daver, Elias Jabbour, et al.
Annals of Hematology|May 12, 2021
Correction to: Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trialMichael Heuser, B Douglas Smith, Walter Fiedler, et al.
Journal of Orthopaedic Research : Official Publication of the Orthopaedic Research Society|January 28, 2014
Prevention of late PJIAntonia Chen, Fares Haddad, Paul Lachiewicz, et al.
American Journal of Hematology|January 23, 2016
Prognostic impact of persistent cytogenetic abnormalities at complete remission in adult patients with acute lymphoblastic leukemiaNicholas J Short, Hagop M Kantarjian, Elias J Jabbour, et al.
Frontiers in Oncology|October 16, 2018
Initial Report of a Phase I Study of LY2510924, Idarubicin, and Cytarabine in Relapsed/Refractory Acute Myeloid LeukemiaPrajwal Boddu, Gautam Borthakur, Mythili Koneru, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 13, 2019
Phase II Trial of MEK Inhibitor Binimetinib (MEK162) in RAS-mutant Acute Myeloid LeukemiaAbhishek Maiti, Kiran Naqvi, Tapan M Kadia, et al.
American Journal of Hematology|March 15, 2016
Long-term evaluation of cardiac and vascular toxicity in patients with Philadelphia chromosome-positive leukemias treated with bosutinibJorge E Cortes, H Jean Khoury, Hagop Kantarjian, et al.
Pageof 59